CRVS

Corvus Pharmaceuticals Inc.

Price

$15.40

return (12m)

195.59%

p/e

-25.27

p/bv

6.07

DIVIDEND YIELD

0.00%

CRVS price

Corvus Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CRVS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

6.94%

3 months

17.74%

1 year

195.59%

2 years

264.07%

5 years

706.28%

10 years

11.51%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals CRVS

Valuation

P/E

-25.27

Sector -4.38

Industry -4.38

P/BV

6.07

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-59.86

Sector -263.09

Industry -263.09

EV/EBIT

-59.73

Sector -702.90

Industry -702.90

P/EBITDA

-24.07

Sector -4.39

Industry -4.39

P/EBIT

-24.01

Sector -4.73

Industry -4.73

P/Total Assets

5.72

Sector 1.49

Industry 1.49

P/Net Current Assets

6.61

Sector -11.70

Industry -11.70

P/Working Capital

6.60

Sector -3.19

Industry -3.19

EPS

-0.59

Sector -2.14

Industry -2.14

BVPS

2.45

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-24.02%

Sector -65.14%

Industry -65.14%

ROA

-22.62%

Sector -65.53%

Industry -65.53%

ROIC

-425.77%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

16.16

Sector 2.90

Industry 2.90

Net Debt / EBITDA

11.17

Sector -6.07

Industry -6.07

Net Debt / EBIT

11.15

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.96

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.94

Sector 0.41

Industry 0.41

Liabilities/Assets

0.06

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

4.59%

Sector -

Industry -

Fundamentals CRVS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CRVS Corvus Pharmaceuticals Inc.	$15.40	189.47%	0.00%	-25.27	6.07	-24.02%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CRVS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (1 people)

United States

12 years

Founded: 2014

2016

Time since IPO - 10 years

42

Employees

Corvus Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.37 billion, with shareholders equity totaling $225.33 million.

The company employs approximately 42 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Corvus Pharmaceuticals Inc. reported $- in revenue, generating net income of $-54.13 million.

Key financial metrics include a P/E ratio of -25.27, a price-to-book (P/B) ratio of 6.07, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CRVS.

Market cap

$1.37 billion

Net worth

$225.33 million

$225,330,000.00

Assets

$239.27 million

$239,270,000.00

Total Shares Outstanding

92.00 million

92,000,000

Average Daily Trading Volume

$1.15 million

$1,147,854.00

Sector

Health Care

Industry

Biotechnology

CRVS

CRVS revenue and profits

Financial Results CRVS

DRAG THE FRAME TO SEE MORE DATA

CRVS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Corvus Pharmaceuticals (CRVS) today?

A cotação de Corvus Pharmaceuticals (CRVS) hoje está em US$ 15.40, com uma variação de 195.59% em relação ao último ano. A cotação de Corvus Pharmaceuticals (CRVS) iniciou o ano negociando na casa dos US$ 7.70 e hoje está em US$ 15.40. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Corvus Pharmaceuticals (CRVS) e dados de ações do Ibovespa e mercados internacionais.

Quando Corvus Pharmaceuticals (CRVS) paga dividendos?

Corvus Pharmaceuticals (CRVS) não distribuiu dividendos no último ano.

Is Corvus Pharmaceuticals (CRVS) a good investment?

Atualmente, Corvus Pharmaceuticals (CRVS) está cotada a US$ 15.40, com um P/L de -25.27, representando um desvio de -1,516% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 195.59 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 195.59%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Corvus Pharmaceuticals (CRVS) stock?

Investir em ações de Corvus Pharmaceuticals (CRVS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Corvus Pharmaceuticals (CRVS) yield today?

A rentabilidade de Corvus Pharmaceuticals (CRVS) foi de 6.94% no último mês, 195.59% no último ano e 706.28% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Corvus Pharmaceuticals (CRVS) hoje, o investimento total seria de US$ 1,540.00, com base na cotação atual de US$ 15.40.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 4,552.09
Em 5 anos: US$ 12,416.71
Em 10 anos: US$ 1,717.25

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CRVS

Corvus Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CRVS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CRVS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc.

United States

12 years

2016

42

PROFIT X PRICE CRVS

Financial Results CRVS

CRVS cash flow

Asset, Revenue and Profit Growth - CRVS

CRVS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions